Xaser94
Established Member
- Reaction score
- 661
If they are just studying already approved drugs for off label uses that would be great. No clinical trials and possibly something new for us. That would be great!
Follica - New Patent Published 2017 - Needling Device And Drug Applicator
If they are just studying already approved drugs for off label uses that would be great. No clinical trials and possibly something new for us. That would be great!
- Reaction score
- 1,003
Maybe the massage effect in Follica is a difference
Yeah massaging probably pushes out all that sebum, the real culprit in Androgenetic Alopecia.
Scientific knowledge of molecular pathways affecting hair growth is on the increase almost monthly it seems. I think the drugs angle will eventually be the cheapest and most effective solution for Androgenetic Alopecia and hair loss due to immune disorders. Already we have the first legit treatment for AA looking very good so far and undergoing clinical trials.
Drugs also look promising for yet another but very different type of hair loss, deafness. Drugs have re-grown cochlear hair cells in mice. This is amazing because mammalian inner ear hair cells don't normally regenerate or repair themselves if damaged, like our scalp and body hair does with the greatest of ease on a cyclical basis. Imagine shaving your whole head, eyebrows and beard and realising none of it will regrow. That's what it's like for deaf people. Once our precious sensorineural cochlear hairs break off from noise damage or age related decline, that's it fini. No mas. It's gone.
Drugs also look promising for yet another but very different type of hair loss, deafness. Drugs have re-grown cochlear hair cells in mice. This is amazing because mammalian inner ear hair cells don't normally regenerate or repair themselves if damaged, like our scalp and body hair does with the greatest of ease on a cyclical basis. Imagine shaving your whole head, eyebrows and beard and realising none of it will regrow. That's what it's like for deaf people. Once our precious sensorineural cochlear hairs break off from noise damage or age related decline, that's it fini. No mas. It's gone.
Last edited:
- Reaction score
- 1,003
my sebum is too concentrated and become like a ball hard according to the doctors.Impossible to evacuate it by a massage in these conditions. It would have to go with the shovel
i 've already read about this.it's amazing
If my hair stands up straight for more than 4 hours, do I have to call my doctor?
your humour have no sense.I don't talk about dermato for my case but this problèm touch several parts of body and scalp too
The evidence you understand anything about sebum lol
Noisette
Established Member
- Reaction score
- 1,341
Some other informations included in the patent.
[000202] In an aspect, it should be appreciated that advantages of the applicators include massaging and parting hair simultaneously while dispensing a chemical, omni-directional movement of the massage heads, a charging station acting as a light pipe and luminous display, buttonless powering, remote control and smart phone application control and monitoring, among other features. A major concern with the use of minoxidil is that it is often mostly applied to the hair rather than directly to the scalp. This is ineffective and inefficient use of the compound as minoxidil must reach the surface of the skin for optimal effect. The applicators deliver drug directly to the skin and the massage mode spreads the drug over the skin providing for more consistent and evenly distributed administration of the drug. A problem with minoxidil administration is that it is typically delivered to the hair and not the scalp. Accordingly, among other advantages, the described drug applicators provide a more effective means of applying the compound to a subject's scalp.
(...) For example, the drug applicator is capable of detecting any one or more of (a) whether a cartridge is provided by the same manufacturer of the drug applicator device or a different manufacturer, (b) what type of compound is in the cartridge, for example, a Minoxidil-5% compound for men or Minoxidil-2% compound for women, (c) how much compound is left in the cartridge, and (d) the usage history of the cartridge, for example, whether this is the first time that this cartridge has been inserted in a drug applicator device or the number of times this cartridge was previously inserted in a drug applicator device.
(...) For example, integumental perturbation can be controlled to limit perturbation to part or all of the epidermis, to part or all of the stratum corneum, or deeper into the papillary dermis, reticular dermis, and/or hypodermis. The occurrence of pinpoint bleeding would indicate removal of the stratum corneum, epidermis (or part thereof) and portions of the upper layer of the dermis, such as the superficial papillary dermis. The occurrence of increased bleeding would indicate deeper penetration (and thus perturbation) into the deeper papillary dermis and reticular dermis layer.
(...) The depth of integumental perturbation depends on the thickness of the skin at a particular treatment area. For example, the skin of the eyelid is significantly thinner than that of the scalp. The occurrence of pinpoint bleeding indicates that the epidermis and portions of the dermis have been removed. Deeper penetration can result in much more bleeding, and the perturbation can go as deep as the hypodermis.
Disruption of the papillary dermis can be detected by the appearance of small pinpoints of blood in the treated area.
(...) [000294] In some embodiments, the hair growth-promoting agent treatment comprises treatment with an antiapoptotic compound. In one embodiment, the antiapoptotic compound is not a Wnt or a Wnt agonist.
(...) [000297] In certain embodiments, the hair growth-promoting agent may be used in its commercially available form. In other embodiments, the form of the hair growth-promoting agent is adjusted to optimize a combination treatment (e.g., integumental perturbation or treatment with another active ingredient) described herein. In a particular embodiment, the hair growth-promoting agent is formulated as a different salt form than that which is commercially available. In a particular embodiment, the hair growth-promoting agent is formulated for topical administration, e.g., by incorporation into a pharmaceutical composition for post-perturbation treatment described in Section 5.2 infra
(...) In some embodiments, the hair growth-promoting agent treatment comprises treatment with a prostaglandin F2a or prostamide analog (e.g., latanoprost, bimatoprost, etc.) in combination with a channel opener (e.g., minoxidil). In one such embodiment, a prostaglandin F2a or prostamide analog is administered in combination with minoxidil.
[000202] In an aspect, it should be appreciated that advantages of the applicators include massaging and parting hair simultaneously while dispensing a chemical, omni-directional movement of the massage heads, a charging station acting as a light pipe and luminous display, buttonless powering, remote control and smart phone application control and monitoring, among other features. A major concern with the use of minoxidil is that it is often mostly applied to the hair rather than directly to the scalp. This is ineffective and inefficient use of the compound as minoxidil must reach the surface of the skin for optimal effect. The applicators deliver drug directly to the skin and the massage mode spreads the drug over the skin providing for more consistent and evenly distributed administration of the drug. A problem with minoxidil administration is that it is typically delivered to the hair and not the scalp. Accordingly, among other advantages, the described drug applicators provide a more effective means of applying the compound to a subject's scalp.
(...) For example, the drug applicator is capable of detecting any one or more of (a) whether a cartridge is provided by the same manufacturer of the drug applicator device or a different manufacturer, (b) what type of compound is in the cartridge, for example, a Minoxidil-5% compound for men or Minoxidil-2% compound for women, (c) how much compound is left in the cartridge, and (d) the usage history of the cartridge, for example, whether this is the first time that this cartridge has been inserted in a drug applicator device or the number of times this cartridge was previously inserted in a drug applicator device.
(...) For example, integumental perturbation can be controlled to limit perturbation to part or all of the epidermis, to part or all of the stratum corneum, or deeper into the papillary dermis, reticular dermis, and/or hypodermis. The occurrence of pinpoint bleeding would indicate removal of the stratum corneum, epidermis (or part thereof) and portions of the upper layer of the dermis, such as the superficial papillary dermis. The occurrence of increased bleeding would indicate deeper penetration (and thus perturbation) into the deeper papillary dermis and reticular dermis layer.
(...) The depth of integumental perturbation depends on the thickness of the skin at a particular treatment area. For example, the skin of the eyelid is significantly thinner than that of the scalp. The occurrence of pinpoint bleeding indicates that the epidermis and portions of the dermis have been removed. Deeper penetration can result in much more bleeding, and the perturbation can go as deep as the hypodermis.
Disruption of the papillary dermis can be detected by the appearance of small pinpoints of blood in the treated area.
(...) [000294] In some embodiments, the hair growth-promoting agent treatment comprises treatment with an antiapoptotic compound. In one embodiment, the antiapoptotic compound is not a Wnt or a Wnt agonist.
(...) [000297] In certain embodiments, the hair growth-promoting agent may be used in its commercially available form. In other embodiments, the form of the hair growth-promoting agent is adjusted to optimize a combination treatment (e.g., integumental perturbation or treatment with another active ingredient) described herein. In a particular embodiment, the hair growth-promoting agent is formulated as a different salt form than that which is commercially available. In a particular embodiment, the hair growth-promoting agent is formulated for topical administration, e.g., by incorporation into a pharmaceutical composition for post-perturbation treatment described in Section 5.2 infra
(...) In some embodiments, the hair growth-promoting agent treatment comprises treatment with a prostaglandin F2a or prostamide analog (e.g., latanoprost, bimatoprost, etc.) in combination with a channel opener (e.g., minoxidil). In one such embodiment, a prostaglandin F2a or prostamide analog is administered in combination with minoxidil.
Piroctone Olamine
If you apply directly after micro needling then you're basically going systemic.
i have all shampoo possible.It's an hormonal problem.The only solution for the moment is to decrease sebum.You can use too doxycicline.It fluidifies sebum
With full hairs coming out of the nose and ears like a werewolf
Noisette
Established Member
- Reaction score
- 1,341
In the patent, we can read this
:
1 . " the hair growth-promoting agent treatment comprises treatment with a prostaglandin F2a or prostamide analog (e.g., latanoprost, bimatoprost, etc.) in combination with a channel opener (e.g., minoxidil).
2. " the hair growth-promoting agent treatment comprises treatment with an antiapoptotic compound "
So maybe, Latanoprost and minoxidil. But I think there are others compounds. Like Professor Rox Anderson (Follica co-funder and professor at Harvard) said
LOL ! I'll ever see it quite the same way again!
The first thing I'll do is run out and get the procedure done along with abandoning you all for all times.
For those of you who choose to remain, remember the next time the wind blows, that I am somewhere not far away, like
